CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, today announced its business objectives for 2013 in conjunction with the 31 st Annual J.P. Morgan Healthcare Conference in San Francisco. Marc Beer, President and Chief Executive Officer, will discuss these objectives as part of a live presentation which will be available on Aegerion's website, www.aegerion.com , on Tuesday, January 8 at 2:00 p.m. PST (5:00 p.m. EST).
"2012 was a year of significant accomplishments for Aegerion culminating with the FDA approval of JUXTAPID in December," said Marc Beer, Chief Executive Officer of Aegerion. "We expect 2013 to be a transformational year for us as a commercial organization as we work to execute on our launch plan and to deliver medicine to patients with homozygous familial hypercholesterolemia (HoFH) in need of treatment."
Mr. Beer continued, "Through our outreach efforts, we continue to identify patients who are potential candidates for therapy and we are well prepared to educate providers about JUXTAPID, and to support patient access. We also plan to make JUXTAPID available on a named patient sale basis in certain of the countries where such sales are permitted based on the U.S. approval. Based on these activities we expect to end 2013 with approximately 250-300 patients on therapy on a global basis, providing a solid base of revenue upon which we expect to build in 2014."JUXTAPID was approved by the U.S. Food and Drug Administration in December 2012 as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non-high-density-lipoprotein cholesterol (non-HDL) in patients with HoFH.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV